全文获取类型
收费全文 | 102912篇 |
免费 | 8545篇 |
国内免费 | 5517篇 |
专业分类
耳鼻咽喉 | 586篇 |
儿科学 | 2594篇 |
妇产科学 | 1266篇 |
基础医学 | 18511篇 |
口腔科学 | 2229篇 |
临床医学 | 8293篇 |
内科学 | 15918篇 |
皮肤病学 | 1797篇 |
神经病学 | 7423篇 |
特种医学 | 1893篇 |
外国民族医学 | 33篇 |
外科学 | 6443篇 |
综合类 | 18526篇 |
现状与发展 | 26篇 |
一般理论 | 1篇 |
预防医学 | 4976篇 |
眼科学 | 1558篇 |
药学 | 10787篇 |
7篇 | |
中国医学 | 3497篇 |
肿瘤学 | 10610篇 |
出版年
2024年 | 121篇 |
2023年 | 1319篇 |
2022年 | 2037篇 |
2021年 | 3691篇 |
2020年 | 3058篇 |
2019年 | 3225篇 |
2018年 | 3114篇 |
2017年 | 3185篇 |
2016年 | 3292篇 |
2015年 | 3430篇 |
2014年 | 5388篇 |
2013年 | 6589篇 |
2012年 | 5427篇 |
2011年 | 6600篇 |
2010年 | 5358篇 |
2009年 | 5406篇 |
2008年 | 5682篇 |
2007年 | 5753篇 |
2006年 | 5455篇 |
2005年 | 5154篇 |
2004年 | 4710篇 |
2003年 | 4163篇 |
2002年 | 3659篇 |
2001年 | 3145篇 |
2000年 | 2752篇 |
1999年 | 2371篇 |
1998年 | 2015篇 |
1997年 | 1766篇 |
1996年 | 1359篇 |
1995年 | 1182篇 |
1994年 | 955篇 |
1993年 | 671篇 |
1992年 | 520篇 |
1991年 | 476篇 |
1990年 | 385篇 |
1989年 | 295篇 |
1988年 | 264篇 |
1987年 | 201篇 |
1986年 | 201篇 |
1985年 | 396篇 |
1984年 | 350篇 |
1983年 | 261篇 |
1982年 | 304篇 |
1981年 | 236篇 |
1980年 | 212篇 |
1979年 | 191篇 |
1978年 | 141篇 |
1977年 | 98篇 |
1976年 | 106篇 |
1975年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
52.
53.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
54.
目的:分析组蛋白去乙酰化酶抑制剂TSA处理前后,食管癌细胞株EC109中差异表达的非编码RNA(ncRNA)和mRNA表达谱,初步预测与TSA作用相关的ncRNA和mRNA。方法:采用MTT、细胞周期等方法检测TSA的效应;运用应用芯片技术分别检测TSA处理前后EC109细胞中ncRNA和mRNA表达谱变化,并对差异ncRNA和mRNA表达谱进行整合分析。结果:TSA以剂量时间依赖方式抑制细胞增殖,细胞周期阻滞和凋亡的发生。芯片检测共发现461个ncRNA和758个mRNA显著性差异表达,生物信息学分析显示差异涉及红比霉素、阿霉素代谢过程、氧化还原、核小体的装配、染色质结构组织和端粒的结构组织等。通过数据库分析预测及整合分析,得到了361个ncRNA-mRNA靶基因对。结论:差异表达的ncRNA和mRNA对TSA的生物学效应密切关联,为进一步研究基因功能及其在肿瘤中的生物学意义奠定基础。 相似文献
55.
56.
目的:评估八段锦干预心力衰竭的疗效及安全性。方法:搜索中国知网数据库、中国生物医学文献数据库、万方数据库以及维普中文全文数据库;PubMed、Cochrane Library、web of science、EMBASE。检索时间为建库至2019年2月28日。对纳入的随机对照试验(RCT)用Cochrane手册进行偏倚风险评估,用Rev Man 5.3软件进行Meta分析。结果:纳入6篇文献,7个随机对照研究,共计543例心力衰竭患者。与对照组比较,观察组MLHFQ减少[MD=10.88,95%CI=(8.22,13.54)],6分钟步行试验(6MWT)提高[MD=107.81,95%CI=(75.83,139.78)],左心室射血分数(LVEF)提高[MD=3.62,95%CI=(2.04,5.19)],B型利钠肽(BNP)降低[MD=73.32,95%CI=(45.12,101.53)],临床疗效[OR=4.00,95%CI=(1.35,11.83)],中医证候评分[OR=4.57,95%CI=(2.03,10.31)]。结论:八段锦可改善心力衰竭患者的心功能,用于稳定期的康复治疗。 相似文献
57.
58.
59.
60.